Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Branford

Showing results (41-50 of 136) with videos related to

Pageof 14
Sort By:
Cancer Genetics and Cytogenetics|February 14, 2009
Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplificationDavid M Ross, Lisa Schafranek, Timothy P Hughes, et al.
Haematologica|October 7, 2021
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkersVaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P Hughes, et al.
Cancer|April 22, 2011
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemiaElias Jabbour, Susan Branford, Giuseppe Saglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteriaSusan Branford, John F Seymour, Andrew Grigg, et al.
Blood|June 16, 2005
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLDeborah White, Verity Saunders, A Bruce Lyons, et al.
Haematologica|September 14, 2014
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinibAdam Olshen, Min Tang, Jorge Cortes, et al.
Blood|October 27, 2015
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyDavid T Yeung, Carine Tang, Ljiljana Vidovic, et al.
Nature|July 1, 2005
Dynamics of chronic myeloid leukaemiaFranziska Michor, Timothy P Hughes, Yoh Iwasa, et al.
Springerplus|June 2, 2016
Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International ScaleChikashi Yoshida, Hirohisa Nakamae, Linda Fletcher, et al.
Acta Haematologica|January 18, 2012
International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from IndiaPoonkuzhali Balasubramanian, Ezhilarasi Chendamarai, Preetha Markose, et al.
Pageof 14

Showing results (41-50 of 136) with videos related to

Sort By:
Pageof 14
Cancer Genetics and Cytogenetics|February 14, 2009
Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplificationDavid M Ross, Lisa Schafranek, Timothy P Hughes, et al.
Haematologica|October 7, 2021
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkersVaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P Hughes, et al.
Cancer|April 22, 2011
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemiaElias Jabbour, Susan Branford, Giuseppe Saglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteriaSusan Branford, John F Seymour, Andrew Grigg, et al.
Blood|June 16, 2005
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLDeborah White, Verity Saunders, A Bruce Lyons, et al.
Haematologica|September 14, 2014
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinibAdam Olshen, Min Tang, Jorge Cortes, et al.
Blood|October 27, 2015
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyDavid T Yeung, Carine Tang, Ljiljana Vidovic, et al.
Nature|July 1, 2005
Dynamics of chronic myeloid leukaemiaFranziska Michor, Timothy P Hughes, Yoh Iwasa, et al.
Springerplus|June 2, 2016
Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International ScaleChikashi Yoshida, Hirohisa Nakamae, Linda Fletcher, et al.
Acta Haematologica|January 18, 2012
International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from IndiaPoonkuzhali Balasubramanian, Ezhilarasi Chendamarai, Preetha Markose, et al.
Pageof 14